[Cancer Research] Molecular, genetic, or pharmacological inhibition of adipose triglyceride lipase impaired human and murine prostate cancer growth in vivo and in cell culture or organoids under conditions mimicking the tumor microenvironment.

[Biochimica Et Biophysica Acta-Reviews On Cancer] The authors summarize the recent studies which mainly focused on the role of tumor microenvironment or bone microenvironment in the CRPC patients with bone metastasis, and discussed the underlying mechanisms.

[Respirology] Human alveolar epithelial cells and macrophages were exposed in vitro to dust and assessed for cytotoxicity and inflammation.

[Cell Reports] Elevated USP13 promoted KRAS-mutant NSCLC metastasis, which was associated with poor prognosis in NSCLC patients.

[Cell Death & Disease] The binding targets and underlying mechanisms of the differentially expressed miRNAs were verified by in vitro and in vivo experiments

[Science Advances] Investigators typed the frequency, phenotype, and function of lymphocytes directed against tumor-associated antigens in 39 consecutive transplanted patients, for 1 year after transplant.

[Haematologica] The authors summarize current knowledge of the pathology and biology of nodal-based peripheral T- and NK- cell lymphomasentities, with an emphasis on recent findings and underlying oncogenic mechanisms.

[FDA] The FDA has received reports of T cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.

[Nature Biomedical Engineering] Investigators showed that replacement of the extracellular domains of heterodimeric cytokine receptors in T cells with two leucine zipper motifs provided optimal Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling.

[blood] The authors presented the clinicogenomic characterization of a CARTITUDE-4 patient who developed a CAR+ T cell lymphoma post cilta-cel. Diagnostic and staging workup included biopsy analyses and FDG-PET scan.

[Cell Stem Cell] Scientists reported the analysis of one year of data from the first cohort of 15 patients enrolled in an open-label, first-in-human, dose-escalation Phase I study to determine the feasibility, safety, and tolerability of the transplantation of allogeneic human neural stem/progenitor cells for the treatment of secondary progressive multiple sclerosis.

[Science Advances] Researchers demonstrated that EpCAM–CAR-T cells costimulated by Dectin-1 exhibited robust antitumor activity without adverse effects in xenograft mouse models and EpCAM-humanized mice.